FDA to Phase Out Animal Testing: Patient Safety Concerns Rise

The U.S. Food and Drug Administration’s ambitious plan to phase out animal testing in drug development is facing a cautious assessment from researchers, who warn that a rapid transition could compromise patient safety. While the move reflects a growing ethical and scientific consensus around reducing animal use, experts emphasize the critical need for rigorous validation of alternative testing methods before fully abandoning established protocols.

A Paradigm Shift in Drug Evaluation

The FDA’s initiative, formally signaled in April 2025, aims to replace animal testing in the development of monoclonal antibodies and other new drugs with what it terms “New Approach Methodologies” (NAMs). These include sophisticated computer modeling, organ-on-a-chip technology – microdevices that mimic the structure and function of human organs – and organoids, three-dimensional cell cultures that resemble miniature organs. The policy change builds on legislation like the FDA Modernization Act 2.0, passed in late 2022, which began to lay the groundwork for accepting alternative data in drug submissions.

The move is driven by a recognition that animal models often fail to accurately predict how drugs will behave in humans, leading to both wasted resources and potential safety risks. The ethical concerns surrounding animal experimentation have fueled a global movement towards more humane and relevant testing strategies. FDA Commissioner Martin A. Makary has described the initiative as “a paradigm shift in drug evaluation” with the potential to accelerate the delivery of safer treatments and lower research and development costs.

Validation: The Critical Hurdle

However, a new academic paper co-authored by researchers at the University of Illinois Urbana-Champaign and Penn State University cautions against a hasty transition. Sara Gerke, from the University of Illinois College of Law and the European Union Center at Illinois, stresses the importance of ensuring that NAMs are demonstrably as effective as, or even superior to, traditional animal testing before they become the standard. “The primary goal of the FDA is to make animal testing the exception in 3-5 years, and a secondary goal is to get drugs to the market faster by reducing research and development costs,” Gerke said. “Those are all worthy and ambitious goals, but it’s hard not to worry about the attendant risks in doing so.”

The researchers acknowledge the FDA’s outlined strategy for reducing animal testing through scientifically validated NAMs, but express concern that many of these technologies are not yet sufficiently mature. “This goal of making animal studies the exception rather than the rule for pre-clinical safety and toxicity testing within the next few years is likely overly optimistic, given the current evidence as well as the absence of noninferiority or superiority studies with the new methodologies,” Gerke explained.

AI and the Potential for Bias

The paper also highlights specific concerns regarding the use of artificial intelligence in drug safety assessment. While AI-powered computational models hold immense promise, they are susceptible to biases embedded in the data used to train them. These biases could lead to inaccurate predictions and potentially compromise patient safety.

Navigating the Path Forward

To mitigate these risks, the researchers propose several strategies. These include stricter oversight of new testing methods, potentially through a premarket review process or independent third-party certification. “Another reasonable approach could be implementing an FDA premarket review or an independent third-party certification process for NAMs,” Gerke suggested. “But at this point, there just needs to be more research that builds out the necessary evidence base for such an alternate approach.”

A more conservative approach would involve continuing animal testing in parallel with NAMs until sufficient data demonstrate the reliability of the alternative methods. The researchers argue, animal testing should remain a requirement until specific alternatives are proven to be fit for purpose. “There’s certainly potential for new methodologies to become an important tool for reducing animal testing. With that said, rigorous validation is essential for these new methods, and we’re just not there yet,” Gerke concluded.

The research, funded by the National Institutes of Health, underscores the complex challenges involved in modernizing drug development while safeguarding public health. The FDA’s commitment to phasing out animal testing represents a significant step forward, but its success hinges on a careful, evidence-based approach to validation and implementation.

The study’s findings come amidst growing scrutiny of the FDA’s expedited drug approval processes. A separate study, published in January 2026 by researchers at the University of Illinois, found that drugs approved under the “Breakthrough Therapy Designation” are associated with a significantly higher number of serious adverse events after reaching the market. This highlights the delicate balance between accelerating access to innovative therapies and ensuring patient safety, a balance that will become even more critical as the FDA moves towards a future with less reliance on animal testing.